Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7283495 | 0.87 | MAPT (0.59) | MAPTSMN1; SMN2POLBMMP1GAA | |
| SCHEMBL3203408 | 0.85 | FABP4 (0.60) | MAPTITGAVSMN1; SMN2POLBHTR6 | |
| SCHEMBL2676737 | 0.82 | FABP4 (0.67) | FABP4ALDH1A1PKLR | |
| SCHEMBL7486079 | 0.79 | SMN1; SMN2 (0.50) | MAPTITGAVSMN1; SMN2HTR6FABP4 | |
| SCHEMBL7414871 | 0.79 | ALDH1A1 (0.55) | MAPTITGAVMMP1GAAMMP12 | |
| SCHEMBL28593071 | 0.79 | SMN1; SMN2 (0.50) | ITGAVSMN1; SMN2HTR6KAT6AALDH1A1 | |
| SCHEMBL10243380 | 0.78 | ITGAV (0.51) | MAPTITGAVSMN1; SMN2POLBHTR6 | |
| SCHEMBL3564486 | 0.78 | L3MBTL1 (0.64) | SMN1; SMN2POLBHTR6ALDH1A1 | |
| SCHEMBL8224006 | 0.76 | HTR6 (0.55) | ITGAVHTR6MMP1KAT6AACLY | |
| SCHEMBL15467870 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBHTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | SHISEIDO COMPANY LTD (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | CUTA, STOM, MTOR | MAPT 2771/4885ITGAV 4753/4885SMN1; SMN2 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.